To evaluate whether a public biotech company’s executives are paid fairly, read its latest definitive proxy statement (DEF 14A) alongside the relevant award terms. Separate salary, annual cash incentives and long-term equity; compare target pay with what was actually earned, vested or forfeited; and assess whether the goals and peer companies fit the issuer’s stage and strategy. A large grant-date value alone does not show what an executive ultimately received or whether pay was well aligned with performance.
Start with the right proxy disclosures
The proxy statement explains the compensation committee’s stated rationale and reports compensation using several different tables. Read the Compensation Discussion and Analysis (CD&A) with the Summary Compensation Table, Grants of Plan-Based Awards table, Outstanding Equity Awards table, Option Exercises and Stock Vested table, potential-payments disclosures, and Pay Versus Performance section. Footnotes and award agreements matter: summary figures can hide vesting conditions, performance requirements, forfeitures, settlement terms or change-in-control treatment.
For each named executive officer, make a simple inventory of fixed salary, annual cash incentive opportunity and long-term equity. Note the target opportunity, actual payout or outcome, performance criteria, vesting schedule, time horizon and treatment upon termination or a change in control. Then consider how the package would change under different outcomes for the company’s share price and stated goals.
Distinguish the compensation measures
Proxy disclosures use measures that answer different questions. Keep the label attached to every figure you compare; none is a universal measure of cash received.
#1 Best Overall
| Measure | What it tells you | What it does not establish by itself |
|---|---|---|
| Grant-date compensation | Reported grant-date values, including the Summary Compensation Table’s values for equity awards, calculated using prescribed valuation methods. | That the executive received that amount in cash, that an award vested, or that it will ultimately be worth the reported value. |
| SEC-defined “compensation actually paid” | A standardized Pay Versus Performance measure that starts with Summary Compensation Table totals and makes specified adjustments, including for pension and equity-award values. | Cash compensation actually received. The measure is not simply cash paid and can reflect valuation changes rather than realized proceeds. |
| Realized or realizable compensation | Company-presented measures intended to describe compensation realized to date or the value of compensation that could be realized under the company’s stated method and date. | A figure comparable across companies without checking definitions, dates, stock-price assumptions and included compensation components. |
When a company presents a custom realized-pay comparison, check its calculation and time period before comparing it with target pay or the SEC’s prescribed measure.
Understand how each award pays out
Equity is not one kind of incentive. Options, restricted stock units (RSUs) and performance stock units or shares (PSUs) expose executives to different risks and potential outcomes. Inspect the award’s actual terms, rather than relying on the category name.
| Award | How value can arise | What to inspect |
|---|---|---|
| Stock options | An option generally has no intrinsic value when the share price is below its exercise price. It can gain value if the share price rises above the strike, subject to vesting and exercise rules. | Exercise price, vesting schedule, expiration, repricing provisions and current share price relative to the strike. Grant-date fair value is not the same as eventual value. |
| RSUs | RSUs can retain stock-linked value as they vest, even if business performance is weak. | Number of shares, vesting period, settlement, forfeiture conditions and any dividend equivalents. Time-based vesting can support retention, but does not necessarily condition payment on a performance goal. |
| PSUs or performance shares | Payment depends on performance conditions; an award may pay nothing if threshold goals are missed. | Metrics and weights, performance period, threshold/target/maximum, payout curve, peer set for relative measures, any absolute-return gates or caps, and committee discretion. Check what was ultimately earned. |
Test whether incentives fit a biotech’s stage
Biotech companies can spend years developing candidates before generating product revenue. A clinical-stage company may therefore use pipeline, clinical, regulatory or other strategic milestones alongside financial or shareholder-return measures. A newly commercial company may also emphasize product revenue or other financial outcomes. The relevant question is not whether a plan uses a particular metric, but whether its disclosed goals are specific enough to evaluate and connected to the company’s strategy.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
For each annual cash incentive and PSU plan, look for defined measures, weights, performance periods, thresholds, target and maximum outcomes, and an explanation of committee certification or discretion. Ask what happens below threshold, at target and above maximum. For operational or pipeline milestones, determine whether the goal was set in advance, can be assessed clearly, and distinguishes success from failure. A milestone’s completion is not automatically evidence of shareholder value creation.
For cash bonuses, also check the balance of corporate and individual goals, any adjustments for unusual items, actual achievement and the committee’s explanation of payout decisions. Compare target opportunities with actual outcomes across multiple years; one year may not show how the program behaves through different business conditions.
Judge the peer group and the committee’s process
Benchmarking can inform pay decisions, but a peer-group median is meaningful only if the comparison companies are relevant. Review peers for stage and business model, size, therapeutic focus, geography and competition for executive talent. Then see how the proxy says the committee used peer data and any compensation consultant’s advice. A list of peers without an explanation of its influence on pay offers limited evidence about the decision.
Also compare the stated purpose of the program with its actual design. If the committee says it rewards long-term performance, examine how much compensation is equity, how long awards take to vest, and whether performance-based awards have measurable goals. Note special grants, changes to prior commitments, discretion and the reasons given for them.
Account for share use and potential dilution
An executive’s equity award has consequences beyond its stated dollar value. Consider the number of shares granted, the available share pool, the company’s share usage or burn rate, outstanding unvested awards and potential dilution. Review whether additional grants have a stated retention or performance rationale, and how much existing unvested equity executives already hold. A large individual grant and a company’s overall dilution profile are related questions, but they are not interchangeable.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Read Pay Versus Performance as a comparison, not a verdict
The SEC’s October 11, 2022 small-entity compliance guide describes Item 402(v) of Regulation S-K. The requirement applies to reporting companies filing proxy or information statements that require executive compensation disclosure, with stated exclusions including foreign private issuers, registered investment companies and emerging growth companies. The table generally covers five completed fiscal years for registrants other than smaller reporting companies (SRCs), and three years for SRCs.
Rank #4
The disclosure reports total compensation and SEC-defined “compensation actually paid” for the principal executive officer and, as an average, the other named executive officers. Required comparisons include company cumulative total shareholder return (TSR), net income and, for registrants other than SRCs, peer-group TSR and a company-selected financial measure. Non-SRCs also list three to seven important financial performance measures. The disclosures are tagged in Inline XBRL.
Use the table to compare compensation measures with performance over time, then examine the company’s accompanying explanation and award terms. It is a standardized view, not a complete assessment of scientific execution or cash compensation received. In particular, the SEC measure’s prescribed valuation adjustments should not be mistaken for a record of cash paid.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Use company examples as illustrations, not benchmarks
Recent company proxies show why there is no single biotech compensation template. These are issuer-reported designs and outcomes, not independent proof that a plan is optimal or representative of the sector.
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
- Adaptimmune Therapeutics plc: Its 2026 proxy describes a market-median target philosophy and an expanded PSU program for all executive officers. The described standard equity mix was 50% RSUs and 50% PSUs; its 2026 PSU measures, relative TSR and MRD revenue CAGR, each had a three-year period and a 50% weight. The filing also reported 98.8% support for its most recent say-on-pay vote.
- Incyte: Its 2026 proxy describes annual cash incentives linked to commercial, research and development, business-development and ESG goals, alongside time-based and performance-based equity.
- Cytokinetics: Its 2026 proxy says the company received its first drug approval in December 2025 and began commercial sales in January 2026. It also says the company had no company-selected financial measure in its Pay Versus Performance disclosure. This transition illustrates why near-term financial comparisons may need to be read alongside strategic and pipeline progress.
- Biogen: Its 2026 proxy says certain performance-share cycles expired with no value after threshold goals were not achieved, and discusses changes to performance-share design following shareholder feedback. It reports a $16.8 million grant-date value for the CEO’s new-hire PSUs, which the company says expired unearned in December 2025. The proxy also reports that the CEO’s realizable pay from his 2022 hire through the end of 2025 was 48% lower than target pay awarded for that period. These figures refer to the filing’s stated awards and time periods; they are not a sector-wide norm.
- Krystal Biotech: Its 2026 proxy describes base salary, performance-based annual cash bonuses and long-term equity awards. It says its committee considered peer-company information and compensation-consultant input, along with executives’ outstanding equity, burn rate and potential dilution. Its explanation distinguishes options, which only deliver value above the exercise price as they vest, from RSUs that retain some value and vest over time.
Issuer proxies explain decisions from the company’s perspective. Treat reported goals, rationales and outcome calculations as disclosures to assess, not independent validation of how difficult a goal was or whether the resulting pay was fair.
A practical checklist for a named company
- What does the committee say the program is meant to achieve, and does the mix of salary, cash incentives and equity match that purpose?
- For each executive, what was targeted, earned, vested, forfeited or still outstanding?
- Are annual bonus and PSU goals, periods, weights and payout ranges disclosed clearly enough to judge?
- What discretion or adjustments did the committee use, and did it explain special awards or changes to earlier commitments?
- Do the peer companies match the issuer’s stage, size, therapeutic focus, geography and talent market?
- What do share usage, unvested awards and potential dilution indicate about the company-wide cost of grants?
- How do TSR and other reported performance measures compare with compensation over time, and what does each compensation measure include?
- Could severance, change-in-control provisions or accelerated vesting materially alter potential payments?
- What was the say-on-pay result, and what specific changes—if any—does the board say it made in response?
Shareholder support is useful context, but it does not replace examining the award design and outcomes. For an issuer-specific judgment, use its latest proxy, award agreements and operating context, including its clinical or commercial stage, share price, capital needs, dilution and voting history.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
